![ECOG-ACRIN logo[19516]275×75](https://blog-ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
September 17, 2024
Fall Comis Symposium to focus on inflammation as a cause of cancer; ECOG-ACRIN readies for NCTN Grant resubmission
September 17, 2024
A conversation with study chair James M. Ford, MD
September 17, 2024
This innovative real-world data study is developing an infrastructure to conduct a study comparing outcomes in patients with EGFR-mutated NSCLC receiving osimertinib with or without chemotherapy and not enrolled in a clinical trial
September 17, 2024
A recent amendment expands eligibility for this phase 2 trial evaluating the use of green tea catechin pills to help prevent progression
September 17, 2024
Summaries of recently published ECOG-ACRIN research results
September 17, 2024
Summaries and links to timely information about research results in medical journals, recognition of research leaders, and more
August 14, 2024
Thoughts on the evolving clinical cancer research environment—and practice-changing results in acute lymphoblastic leukemia
August 22, 2024
This phase 3 study is comparing BRAF-targeted therapy with dabrafenib-trametinib to TKI therapy with cabozantinib in patients with disease progression following standard treatments
August 14, 2024
A Scientific Member of ECOG-ACRIN since 2012
August 14, 2024
Summaries of recently published ECOG-ACRIN research results
August 14, 2024
Summaries and links to timely information about research results in medical journals, recognition of research leaders, and more
July 3, 2024
GI Cancer Committee displays strong representation at ASCO; real-world data study nears activation; ECOG-ACRIN commends NCI's appointment of senior advisor for clinical research